Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 11/20 | 0.61 |
| ▸ | CA2 | P00918 | 11/20 | 0.61 |
| ▸ | CA12 | O43570 | 5/20 | 0.59 |
| ▸ | CA9 | Q16790 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | PTPRC | P08575 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857194 | 0.86 | MAPT (0.58) | KMT2AL3MBTL1MAPTALDH1A1PTPRC | |
| SCHEMBL13764399 | 0.83 | CA1 (0.72) | KMT2AL3MBTL1CA1CA2CA12 | |
| SCHEMBL14183612 | 0.82 | MGLL (0.65) | KMT2AL3MBTL1CA1CA2CA12 | |
| SCHEMBL839348 | 0.81 | NAMPT (0.66) | KMT2AMAPTALDH1A1PTPRCPTPN1 | |
| SCHEMBL7649333 | 0.79 | PTPRC (0.60) | KMT2AMAPTALDH1A1PTPRCPTPN1 | |
| SCHEMBL25547337 | 0.79 | PTPRC (0.60) | KMT2AMAPTALDH1A1PTPRCPTPN1 | |
| SCHEMBL418094 | 0.79 | MEN1 (0.60) | KMT2AL3MBTL1MAPTALDH1A1PTPRC | |
| SCHEMBL13316189 | 0.79 | MAPK1 (0.67) | KMT2AMAPTALDH1A1PTPRCPTPN1 | |
| SCHEMBL25738387 | 0.78 | CA1 (0.80) | KMT2ACA1CA2CA12CA9 | |
| SCHEMBL2349758 | 0.78 | NAMPT (0.70) | KMT2AMAPTALDH1A1PTPRCPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-8614215-B2 | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) | MERCK SERONO SA (CH) | 2013-12-24 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| EP-2118076-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | Merck Serono S.A. (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | PFKP, PDXK, PF4 | KMT2A 3444/4885L3MBTL1 2836/4885CA1 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.